Health Catalyst (HCAT) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Canaccord Genuity | Downgraded | Buy → Hold | $1.80 from $3.00 | Aug 21, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $1.50 from $1.75 | Aug 13, 2026 |
| Citigroup | Maintained | Neutral | $2.00 from $2.50 | Aug 11, 2026 |
| Canaccord Genuity | Maintained | Buy | $3.00 from $2.00 | Jul 21, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $1.75 from $1.00 | Jun 26, 2026 |
| Stephens & Co. | Maintained | Equal-Weight | $1.75 from $2.00 | May 12, 2026 |
| Cantor Fitzgerald | — | Neutral | — | May 11, 2026 |
| Wells Fargo | Downgraded | Overweight → Equal-Weight | $1.00 from $5.00 | Mar 18, 2026 |
| Cantor Fitzgerald | Maintained | Neutral | $3.00 from $4.00 | Mar 13, 2026 |
| Stifel | Maintained | Hold | $2.00 from $3.75 | Mar 13, 2026 |
| Stephens & Co. | Maintained | Equal-Weight | $2.00 from $3.50 | Mar 13, 2026 |
| Canaccord Genuity | Maintained | Buy | $2.00 from $5.00 | Mar 13, 2026 |
| Citigroup | Maintained | Neutral | $1.75 from $2.75 | Mar 13, 2026 |
| Citigroup | Maintained | Neutral | $2.75 from $3.25 | Jan 9, 2026 |
| Wells Fargo | Maintained | Overweight | $5.00 from $6.00 | Nov 11, 2025 |
| Stifel | Maintained | Hold | $3.75 from $4.50 | Nov 11, 2025 |
| Citigroup | Maintained | Neutral | $3.25 from $3.50 | Nov 11, 2025 |
| Keybanc | Maintained | Overweight | $4.00 from $5.00 | Oct 8, 2025 |
| Evercore ISI Group | Maintained | In-Line | $3.00 from $4.00 | Oct 8, 2025 |
| Cantor Fitzgerald | Maintained | Neutral | $4.00 | Oct 7, 2025 |
Frequently asked questions
What is the price target for HCAT stock?
The average 12-month analyst price target for Health Catalyst (HCAT) is $1.77, with a high estimate of $2.00 and a low of $1.50, across 3 analysts.
Is HCAT a buy, sell, or hold?
Analysts covering Health Catalyst currently average a Hold rating: 1 buy, 5 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for HCAT?
The average price target of $1.77 implies 9.05% upside from the last price of $1.62.
What is the latest analyst rating on HCAT?
On Aug 21, 2026, Canaccord Genuity downgraded Health Catalyst to Hold with a price target of $1.80.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.